Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Recurium Ip Holdings LLC manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are 4 pending office actions currently active, which are assigned to 4 distinct examiners. This distribution ensures that each pending matter is reviewed by a different individual, providing a variety of perspectives on the company's intellectual property. The involvement of 3 distinct art units suggests that the portfolio covers several specialized fields within the biotechnology sector, requiring a broad strategic approach.
The busiest examiner, HEITMEIER, KENDALL NICOLE, is responsible for 1 pending office action. Since the total count of pending office actions is 4, the workload is spread across the examining staff. This lack of concentration means that the company must manage 4 separate prosecution timelines and examiner relationships. Practitioners should be prepared for a decentralized process where the results of one office action may not predict the outcomes of the others, as the 1 pending action per examiner ensures a balanced workload.
With 4 distinct examiners operating across 3 distinct art units, there is a concentration of activity within at least one art unit. This overlap requires a coordinated strategy to maintain consistency in technical arguments across the 3 distinct art units. The busiest examiner's load of 1 pending office action highlights the distribution of the 4 total actions. This structure necessitates a broad management approach to handle the diverse requirements of the different examiners and art units involved in the company's patent prosecution.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (50%) |
| §103 only | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HEITMEIER, KENDALL NICOLE | 1 | 65.1% | +41.1% |
| SHOWALTER, ALEXANDER KEITH | 1 | 55.4% | +27.3% |
| SZNAIDMAN, MARCOS L | 1 | 37.4% | +16.1% |
| TOWNSLEY, SARA ELIZABETH | 1 | 25.6% | +48.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18634055 | COMBINATIONS OF WEE1 INHIBITORS AND ANTI-CD47 ANTIBODIES | HEITMEIER, KENDALL NICOLE | — |
| 18389654 | WEE1 INHIBITORS AND METHODS FOR TREATING CANCER | SHOWALTER, ALEXANDER KEITH | — |
| 17998561 | MONO- AND COMBINATION THERAPIES | TOWNSLEY, SARA ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18554951 | WEE1 COMPOUND FOR TREATING UTERINE SEROUS CARCINOMA | SZNAIDMAN, MARCOS L | 11d overdue |
| 18634055 | COMBINATIONS OF WEE1 INHIBITORS AND ANTI-CD47 ANTIBODIES | HEITMEIER, KENDALL NICOLE | — |
| 18389654 | WEE1 INHIBITORS AND METHODS FOR TREATING CANCER | SHOWALTER, ALEXANDER KEITH | — |
| 17998561 | MONO- AND COMBINATION THERAPIES | TOWNSLEY, SARA ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1629 | 2 |
| 1621 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18634055 | COMBINATIONS OF WEE1 INHIBITORS AND ANTI-CD47 ANTIBODIES | HEITMEIER, KENDALL NICOLE | 1621 | §101§103§112DP | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18389654 | WEE1 INHIBITORS AND METHODS FOR TREATING CANCER | SHOWALTER, ALEXANDER KEITH | 1629 | §101§103§112Other | Non-Final OA | — | Pending | Dec 19, 2023 |
| 18554951 | WEE1 COMPOUND FOR TREATING UTERINE SEROUS CARCINOMA | SZNAIDMAN, MARCOS L | 1628 | §103Other | Non-Final OA | 11d overdue | Pending | Oct 11, 2023 |
| 17998561 | MONO- AND COMBINATION THERAPIES | TOWNSLEY, SARA ELIZABETH | 1629 | §103 | Final Rejection | — | Pending | Nov 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRecurium Ip Holdings LLC has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Kendall Nicole Heitmeier has the most, with 1 of Recurium Ip Holdings LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
